Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis:protocol for a multicentre randomised controlled trial by Svensson, Annemarie Lyng et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Multifactorial intervention to prevent cardiovascular disease in patients with early
rheumatoid arthritis
Svensson, Annemarie Lyng; Christensen, Robin; Persson, Frederik; Løgstrup, Brian Bridal;
Giraldi, Annamaria; Graugaard, Christian; Fredberg, Ulrich; Blegvad, Jesper; Thygesen, Tina;
Hansen, Inger Marie Jensen; Colic, Ada; Bagdat, Döne; Ahlquist, Palle; Jensen, Hanne Slott;
Hørslev-Petersen, Kim; Sheetal, Ekta; Christensen, Torben Grube; Svendsen, Lone;
Emmertsen, Henrik; Ellingsen, Torkell
Published in:
B M J Open
DOI:
10.1136/bmjopen-2015-009134
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Svensson, A. L., Christensen, R., Persson, F., Løgstrup, B. B., Giraldi, A., Graugaard, C., ... Ellingsen, T. (2016).
Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol
for a multicentre randomised controlled trial. B M J Open, 6(4), [e009134]. https://doi.org/10.1136/bmjopen-
2015-009134
Download date: 03. Feb. 2020
Multifactorial intervention to prevent
cardiovascular disease in patients with
early rheumatoid arthritis: protocol for a
multicentre randomised controlled trial
Annemarie Lyng Svensson,1 Robin Christensen,2 Frederik Persson,3
Brian Bridal Løgstrup,4 Annamaria Giraldi,5 Christian Graugaard,6 Ulrich Fredberg,7
Jesper Blegvad,7 Tina Thygesen,7 Inger Marie Jensen Hansen,8 Ada Colic,9
Döne Bagdat,9 Palle Ahlquist,10 Hanne Slott Jensen,1 Kim Hørslev-Petersen,11
Ekta Sheetal,12 Torben Grube Christensen,13 Lone Svendsen,14
Henrik Emmertsen,15 Torkell Ellingsen12,16
To cite: Svensson AL,
Christensen R, Persson F,
et al. Multifactorial
intervention to prevent
cardiovascular disease in
patients with early
rheumatoid arthritis: protocol
for a multicentre randomised
controlled trial. BMJ Open
2016;6:e009134.
doi:10.1136/bmjopen-2015-
009134
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-009134).
Received 22 June 2015
Revised 19 September 2015
Accepted 14 October 2015
For numbered affiliations see
end of article.
Correspondence to
Professor Torkell Ellingsen;
torkell.ellingsen@rsyd.dk
ABSTRACT
Introduction: Cardiovascular morbidity is a major
burden in patients with rheumatoid arthritis (RA). In this
study, we compare the effect of a targeted, intensified,
multifactorial intervention with that of conventional
treatment of modifiable risk factors for cardiovascular
disease (CVD) in patients with early RA fulfilling the
2010 American College of Rheumatology European
League Against Rheumatism (ACR/EULAR) criteria.
Methods and analysis: The study is a prospective,
randomised, open label trial with blinded end point
assessment and balanced randomisation (1:1)
conducted in 10 outpatient clinics in Denmark. The
primary end point after 5 years of follow-up is a
composite of death from cardiovascular causes, non-
fatal myocardial infarction, non-fatal stroke and cardiac
revascularisation. Secondary outcomes are: the
proportion of patients achieving low-density lipoprotein
cholesterol <2.5 mmol/L, glycated haemoglobin
<48 mmol/mol, blood pressure <140/90 mm Hg for
patients without diabetes and <130/80 mm Hg for
patients with diabetes and normoalbuminuria (urinary
albumin creatinine ratio <30 mg/g) after 1 year of
follow-up and the proportion of patients in each
treatment group achieving low RA disease activity after
1 year, defined as a disease activity score C-reactive
protein (DAS28-CRP) <3.2 and a DAS28-CRP score
<2.6 after 12, 24 and 60 months. Furthermore, all
hospitalisations for acute and elective reasons will be
adjudicated by the event committee after 12, 24 and
60 months. Three hundred treatment-naive patients
with early RA will be randomly assigned (1:1) to
receive either conventional treatment administered and
monitored by their general practitioner according to
national guidelines (control group) or a stepwise
implementation administered and monitored in a
quarterly rheumatological nurse-administered set-up of
behaviour modification and pharmacological therapy
targeting (1) hyperlipidaemia, (2) hypertension, (3)
hyperglycaemia and (4) microalbuminuria (intervention
group).
Ethics and dissemination: This protocol is
approved by the local ethics committee (DK-S-
2014007) and The Danish Health and Medicines
Authority. Dissemination will occur through
presentations at National and International conferences
and publications in international peer-reviewed
journals.
Trial registration number: NCT02246257
INTRODUCTION
Cardiovascular disease (CVD) is a major
burden in patients with rheumatoid arthritis
(RA), and the risk of myocardial infarction
(MI) in patients with RA generally corre-
sponds to the risk in 10-year older patients
without RA.1 2 Moreover, patients with RA
have a reduced life expectancy.3 4 In a
meta-analysis that included 41 490 patients
with RA, the risk of CVD was increased by
48% and that of MI by 68% compared with
the general population.5 The risk of CVD
associated with RA is signiﬁcantly increased
compared with healthy individuals and is
comparable with that seen in type 2 diabetes
mellitus (T2DM).6 RA itself should be
regarded as a strong independent cardiovas-
cular risk factor for which cardiovascular risk
management like that used in (T2DM)
should be considered.6 It has been shown
that the risk of both MI and stroke is
doubled among patients with RA who visited
their doctor at least thrice for RA during a
5-year period, compared with patients
without RA visiting their doctor thrice.7
Furthermore, the risk of MI has been shown
to be increased in young women within the
ﬁrst 3 years of RA treatment.2 8
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Results from the Norfolk arthritis register showed
that the risk of hospitalisation for CVD was approxi-
mately doubled in patients with early seropositive
inﬂammatory RA compared with the general popula-
tion.9 In a previous study, patients with RA had a sub-
stantially increased risk of death following MI but not
stroke at 30-day follow-up, compared with patients
without RA.10 11
Data from the Nurses’ Health Study showed that
patients with RA and hyperlipidaemia had an excessive
risk of MI which was four times higher compared with
patients with RA without hyperlipidaemia.12 More than
50% of patients with early RA had abnormal lipid
levels at the time of diagnosis; however, increased
inﬂammatory control for 2 years did not inﬂuence the
hyperlipidaemic status.13 Discontinuation of statin
therapy for ≥3 consecutive months in patients with RA
was associated with a 60% increased risk of death from
CVD.3
Patients with RA have an increased risk of sexual impe-
diments, presumably due to a combination of biological,
psychological, social and iatrogenic factors.14–17
Moreover, hyperlipidaemia is a well-known risk factor in
the pathogenesis of sexual dysfunction.16–18 Endothelial
dysfunction contributes to the pathogenesis of both
CVD and common forms of erectile dysfunction (ED)
and CVD. Some studies have shown that ED onset and
severity are associated with an increased expression of
markers of inﬂammation.18–20 The sexual ramiﬁcations
of RA in combination with cardiovascular disease have,
however, never been thoroughly investigated, and this
cohort therefore offers a unique and prospective insight
into the sexual function and quality of life of these
patients.
To the best of our knowledge, this is the ﬁrst study to
investigate intensive interventions in a randomised
setting aiming at prevention of CVD in treatment-naive
patients with early RA.
Rationale
A targeted, intensiﬁed multifactorial intervention of
modiﬁable risk factors for CVD in patients with T2DM
with microalbuminuria is more effective in preventing
cardiovascular death than conventional treatment.20 21
Thus, the primary aim of our present study is to evaluate
the effect of a targeted, intensiﬁed, multidimensional
intervention compared to conventional treatment of
modiﬁable risk factors for CVD in patients with early
RA. The primary end point, a composite of death from
cardiovascular causes, non-fatal MI, non-fatal stroke and
revascularisation, will be assessed after 5 years’ of
follow-up.
Objective
To evaluate the effect of a targeted, intensiﬁed, multidi-
mensional intervention compared with conventional
treatment of modiﬁable risk factors for CVD in patients
with early RA.
METHODS
Trial design
The study is a prospective, randomised, open label trial,
blinded end point outcome assessment22 with balanced
randomisation (1:1) conducted in 10 outpatient clinics
in Denmark. Follow-up visits for patients in the interven-
tion group are scheduled to occur at baseline and then
after 2, 4 and 12 weeks and thereafter every third month
for 5 years after randomisation (see ﬁgure 1). The
control group will be monitored for RA disease activity
and comorbidity after 2, 4 and 12 weeks and thereafter
following national guidelines for RA.23 Prevention of
CVD risk factors in the control group will be treated in
general practice according to national guidelines for
diabetes (2011), hypertension (2009) and CVD
(2013).24–26 A closeout visit will take place after study
termination. Recruitment will begin in September 2014
and is scheduled to be completed at the end of
September 2020.
Participants
The participants in the study have RA diagnosed by the
treating rheumatologist.
Key inclusion criteria: RA according to the revised
American College of Rheumatology (ACR) 2010 cri-
teria27 and plasma low-density lipoprotein (LDL)
>2.5 mmol/L.
Exclusion criteria: Previous disease-modifying anti-
rheumatic drug (DMARD) or oral glucocorticoid treat-
ment, pregnant or lactating women, current infection
with parvovirus B19, hepatitis B, hepatitis C or HIV or
any condition contraindicating the study medication
and a previous report of hospitalisation for myocardial
ischaemia deﬁned as follows: (1) non-fatal MI deﬁned
according to national and international guidelines, (2)
acute coronary syndrome (ACS) including acute ischae-
mic symptoms with possible biomarker changes or ECG
changes that do not meet the criteria for MI, (3) angina
pectoris, (4) revascularisation (percutaneous coronary
intervention (PCI) or coronary artery bypass grafting
(CABG) (Box 1).
Other requirements for inclusion are willingness to
participate for the duration of the trial. All patients will
receive verbal and written information about the trial
and sign a consent form before inclusion. The study
nurse obtains written consent before inclusion and
randomisation.
Interventions
At baseline, when the diagnosis of RA is established,
blood samples for LDL, DMARD, glycated haemoglobin
(HbA1c) and urine for microalbuminuria will be rou-
tinely taken. After 2 weeks, patients will be invited to par-
ticipate in the study if they have LDL>2.5 mmol/L and
none of the exclusion criteria.
After written consent is obtained, patients will be ran-
domised to either receive (1) Intensiﬁed multidimen-
sional intervention involving strict treatment goals
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according to national guidelines or (2) Conventional
treatment for multiple risk factors from their general
practitioner (GP) according to the national guidelines
for diabetes (2011), CVD (2013) and hypertension
(2009)24–26 with the possibility of being referred to spe-
cialists. The GP will receive an electronic notiﬁcation to
treat diabetes, hypertension or CVD if present. The
patient has to arrange the appointment with the GP.
The GP does not receive information about the
ERACORI study protocol or the study hypothesis, but is
of course free to search for the study in http://www.
clinicaltrials.gov.All patients will ﬁll out the short form
12-items health survey (SF-12) and Changes in Sexual
Functioning Questionnaires (CSFQ), and disease activity
score C-reactive protein (DAS28-CRP) will be registered
using the Danish Danbio registry. LDL, DMARD, HbA1c
and microalbuminuria will be measured.
1. In the intervention group, all patients will receive
40 mg simvastatin according to national guidelines.
Stepwise introduction of pharmacological therapy tar-
geting (1) hyperlipidaemia, (2) hypertension, (3)
hyperglycaemia and (4) microalbuminuria and
behaviour modiﬁcation will be controlled by the
project team. (1)Patients with adverse effects to ﬁrst-
line statin will be treated with 80 mg atorvastatin and
subsequently treated with ezetimibe 10 mg if side
effects to atorvastatin are seen.28 Patients whose
hyperlipidaemia is subsequently judged by their phys-
ician to require additional lipid-lowering therapy or
treatment could be added to trial treatment. The
target is LDL cholesterol <2.5 mmol/L.25
2. At each follow-up visit, antihypertensive drug therapy
will be titrated to achieve target blood pressures
(<140–90 mm Hg) for patients without diabetes and
(<130–80 mm Hg) for patients with diabetes.24 25
The primary drug of choice is an angiotensin-II
receptor antagonist at the maximal recommended
dose if tolerated. All patients with microalbuminuria
(urinary albumin creatinine ratio 30–299 mg/g)29 30
will be treated with an angiotensin-II receptor antag-
onist if other causes, for example, urinary tract infec-
tion, can be ruled out. Combination treatment with
an angiotensin-II receptor antagonist and an ACE
inhibitor or a renin inhibitor will not be advised.
3. HbA1c levels above 48 mmol/mol (6.5%) will be
treated with metformin.25
4. Patients in the intervention group have in-person
contact with the study team every third month with
response on LDL cholesterol, HBA1c and blood pres-
sure. Every 6 months, a counselling session regarding
diet, smoking, alcohol use and exercise habits is pro-
vided by the study nurse. Additional phone calls
between the scheduled visits if further counselling
regarding treatment is required (ﬁgure 2).
Figure 1 Trial design, visits and end points. BP, blood pressure; CRP, C reactive protein; CSFQ, Changes in Sexual
Functioning Questionnaires; DAS28, disease activity score 28; HAQ, Health Assessment Questionnaire; HbA1c, glycated
haemoglobin; LDL, low-density lipoprotein; RA, rheumatoid arthritis; VAS, visual analogue scale.
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Behavioural change and behavioural risk factors for
CVD (KRAM): Lifestyle recommendations according to
the European Heart Society31 32 are no smoking, weight
reduction if body mass index (BMI≥25 kg/m2), espe-
cially if BMI≥30 kg/m2, 30 min of moderately vigorous
exercise on most days of the week and a healthy diet.
Stopping smoking is encouraged in all smokers.
Nicotine chewing gum and transdermal nicotine patches
have been widely used in helping quitters to go through
the initial difﬁcult weeks/months of smoking cessation,
and will be recommended to all smokers.
Physical activity with vigorous exercise on most days of
the week will be recommended. Also recommended will
be a healthy diet that includes a wide variety of foods
and energy intake adjusted to avoid overweight. The diet
should consist of fruits and vegetables, wholegrain
cereals and bread, ﬁsh (especially oily), lean meat, low
fat dairy products and replacement of saturated fat with
monounsaturated and polyunsaturated fats.
Hypertensive patients should reduce salt intake. The
Danish National Board of Health advises no more than
14 units of alcohol per week for men and 7 units per
week for women.33
Treatment algorithm RA: The start dose of oral metho-
trexate is 15 mg/week, increasing the dose by 5 mg
every second week to 25 mg after 4 weeks. If a swollen
joint is observed or at any other later visit, it is injected
with glucocorticoids (kenalog-trimacinalone). If a
swollen joint is observed after 6 weeks or at any later
visit, daily orally 200 mg hydroxychloroquine and
2000 mg SalazopyrinEntabs will be added and orally
methotrexate changed to 25 mg subcutaneously/week.
If DAS28-CRP <2.6 at year 1 and no swollen joints are
observed, treatment will be tapered to 15 mg methotrex-
ate weekly. If unacceptable side effects occur, the route
Figure 2 Cardiovascular treatment algorithm—Stepwise Guideline Intervention ERACORI Study.
Box 1 Eligibility criteria at a glance
Inclusion
▸ Age >18 years
▸ Early rheumatoid arthritis (American College of Rheumatology
2010 criteria)
▸ Plasma low-density lipoprotein >2.5 mmol/L
▸ Disease-modifying antirheumatic drug (DMARD) Naïve
▸ Steroid Naïve
Exclusion
▸ Pregnancy
▸ Lactation
▸ Ongoing/previous DMARD therapy
▸ Ongoing/previous steroid therapy
▸ Contraindications to any of the trial drugs
▸ Current infection with parvovirus B19, hepatitis B, hepatitis C
or human immune deficiency virus. Previous report of hospi-
talisation for myocardial ischaemia defined as follows: (1) non-
fatal myocardial infarction (MI) defined according to national
and international guidelines, (2) acute coronary syndrome
including acute ischaemic symptoms with possible biomarker
changes or electrocardiographic changes that do not meet the
criteria for MI, (3) angina pectoris, (4) revascularisation (per-
cutaneous coronary intervention or coronary artery bypass
grafting).
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of administration can be changed to subcutaneous
methotrexate at the same dose. The dose escalation
should be guided by efﬁcacy and/or adverse events. See
ﬁgure 3. Furthermore, swollen joints can be injected with
glucocorticosteroids according to the chart (maximum 4
joints or 4 mL per visit, according to the CIMESTRA
algorithm previously published.34 If subsequently, evalu-
ated in a 3-monthly setting, disease activity preceded
higher than DAS28-CRP 3.2, initiation and treatment
with biologics will be applied according to national
guidelines.23 Oral glucocorticoids will not be allowed.
All patients will receive folic acid as well as calcium
and vitamin D supplementation in accordance with
national guidelines.
The ERACORI programme will be administered simi-
larly at all sites. All study sites are included after a
meeting with the principal investigator, the
co-investigator, the local investigator and their study
team. The purpose is to discuss the study and the prac-
tical aspects. Additional meetings will be arranged when
necessary. Phone calls and emails are used to clear
day-to-day questions with the co-investigator or principal
investigator. All study sites are provided with an
ERACORI trial site ﬁle. All included patients have a ﬁle
with a checklist of scheduling patient visits for the
physician or nurse, when to control blood tests (week -2
and to 60 months). There is a checklist for all patient
visits stating what is supposed to take place at every visit.
Patient information, informed consent ﬁle and the rele-
vant questionnaires in hard copy for all study visits are
included as well. Data are registered in the Danish
Danbio Registry. All investigators are entering data on the
study participants into the same module using individual
usernames, passwords and user rights. This makes it pos-
sible for the co-investigator once a year to audit if all
information is entered as planned in the Danbio Registry.
Outcomes
The primary outcome: The primary cardiovascular
disease end point will be a composite measure of death
from cardiovascular causes, non-fatal MI, non-fatal
stroke and cardiac revascularisation after 5 years’ of
follow-up.
The event committee will adjudicate all deaths from
any cause. Death will be classiﬁed as either cardiovascu-
lar or non-cardiovascular as illustrated in ﬁgure 4. If no
non-cardiovascular cause can be identiﬁed, the cause of
death will always be considered as being cardiovascular.
Cardiovascular deaths will be further classiﬁed in rela-
tion to time as either sudden or non-sudden. Sudden
Figure 3 Early RA intervention algorithm. BP, blood pressure; CRP, C-reactive protein; CSFQ, Changes in Sexual Functioning
Questionnaires; DAS28, disease activity score 28; DMARD, disease-modifying antirheumatic drug; GP, general practitioner;
HAQ, Health Assessment Questionnaire; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; MTX, methotrexate; RA,
rheumatoid arthritis; SF-12, short form 12-items health survey; VAS, visual analogue scale.
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deaths are described as either (1) witnessed and instant-
aneous or occurring within 1 h of new symptoms or (2)
unwitnessed with no apparent cause (found dead). The
remaining cardiovascular deaths will be classiﬁed as
non-sudden.
Cardiovascular deaths will be subclassiﬁed as caused
by (1) MI, (2) heart failure, (3) stroke, (4) documented
arrhythmia, (5) procedure-related, (6) other cardiovas-
cular causes including pulmonary embolism or (7) pre-
sumed cardiovascular death.
1. Death due to MI is deﬁned as a primary fatal event
that occurs within 7 days of an MI documented by
autopsy or an MI deﬁned according to national and
international guidelines.
2. Death due to heart failure is deﬁned as death occur-
ring after a period of increasing symptoms and signs
of heart failure.
3. Death due to stroke is deﬁned as development of
acute severe neurological deﬁcit with or without
documentation by CT scan. Deaths occurring within
2 weeks of a stroke where no other competing causes
can be identiﬁed are classiﬁed as death due to stroke.
Death from stroke occurring as a direct consequence
of an investigation/procedure/operation will be clas-
siﬁed as procedure-related death.
4. Death due to documented arrhygmia as primary
cause of death.
5. Death due to procedure-related death is deﬁned as
death following a cardiovascular investigation/pro-
cedure/operation within 24 h.
6. Death due to other cardiovascular causes is death
occurring after other cardiovascular events like, for
example, pulmonary embolism, ruptured aortic
aneurysm, etc.
7. Presumed cardiovascular death is all deaths not
attributed to the above categories of cardiovascular
deaths or not attributed to a documented non-
cardiovascular cause. This category includes deaths
from unknown cause.
Non-cardiovascular death will be classiﬁed as one
caused by cancer, primary infectious disease, respiratory
disease, trauma/accident, suicide or other causes for
non-cardiovascular death as illustrated in ﬁgure 4.
The adjudication for cause of death, non-fatal MI,
non-fatal stroke and cardiac revascularisation will be
based on information from patient records, the
death certiﬁcate and information from the GP. Two
members of the event committee will adjudicate each
event separately. In case of disagreement between the
two members of the event committee, there will be a
meeting between these two members and the chair-
man of the committee will make a decision in each
case.
Both members of the event committee will be blinded
to patient treatment allocation.
Secondary outcome: Secondary outcomes are the pro-
portion of patients achieving LDL cholesterol
<2.5 mmol/L, HbA1c <48 mmol/mol (HbA1c <6.5%),
blood pressure <140/90 mm Hg for patients without dia-
betes and <130/80 mm Hg for patients with diabetes
and normoalbuminuria (urinary albumin creatinine
ratio <30 mg/g) after 1-year of follow-up24–26; this is in
agreement with present national guidelines, which will
be adjusted according to any future changes in the
respective national guidelines. Secondary outcomes are
the proportion of patients in each group achieving low
RA disease activity after 1-year: DAS28-CRP<3.2 and
DAS28-CRP<2.6 at 12, 24 and 60 months. Furthermore,
Figure 4 Classification of death in the trial.
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all to hospitalisations will be adjudicated by the event
committee and hospitalisation will be deﬁned as
1. Hospitalisation for acute medical reasons;
2. Hospitalisation for planned, elective reasons.
Hospitalisations for acute medical reasons are classiﬁed
as cardiovascular or non-cardiovascular. An acute hospi-
talisation is deﬁned as non-planned and must include a
stay in hospital for at least one night, that is, a minimum
covering two consecutive dates and accompanied by a cal-
endar date change. This classiﬁcation will be based on
the total ﬁndings from the whole hospital admission.
Cardiovascular acute hospitalisations are further classi-
ﬁed as due to (1) worsening heart failure, (2) myocardial
ischaemia, (3) arrhythmia, (4) stroke, (5) other cardio-
vascular hospitalisations or (6) presumed cardiovascular
hospitalisation. The classiﬁcation is as follows:
1. Hospitalisation for worsening heart failure is deﬁned
as a non-planned admission to hospital lasting at
least one night and presenting symptoms or signs
related to congestive heart failure. Furthermore,
objective ﬁndings and an increase in congestive heart
failure treatment will be evaluated.
2. Hospitalisation for myocardial ischaemia is deﬁned as
follows:
a. Non-fatal MI is deﬁned according to national
and international guidelines.
b. ACS including acute ischaemic symptoms with
possible biomarker changes or electrocardio-
graphic changes which do not meet the criteria
for MI.
c. Angina pectoris.
d. Revascularisation (PCI or CABG).
3. Hospitalisation due to supraventricular and ventricu-
lar arrhythmias.
4. Hospitalisation for stroke is deﬁned as haemorrhagic
and ischaemic stokes and transient ischaemia attacks.
5. Hospitalisation for other cardiovascular reasons
such as pulmonary embolism or ruptured aortic
aneurism.
6. Hospitalisation for a presumed cardiovascular reason
is deﬁned as no non-cardiovascular cause identiﬁed.
Non-cardiovascular hospitalisation for acute medical
reasons is classiﬁed as due to cancer, infection,
respiratory disease, trauma/accident, suicide or other
causes.
Hospitalisation for planned, elective reason is divided
into cardiovascular or non-cardiovascular, and cardiovas-
cular hospitalisations are further divided into hospitalisa-
tion for myocardial ischaemia, arrhythmias, heart failure
or other cardiovascular hospitalisations. Non-cardiovas-
cular hospitalisation for planned reasons is not further
subdivided (ﬁgure 5).35–37
All hospitalisations will be adjudicated by the event
committee as illustrated in ﬁgure 5.
Secondary outcomes deﬁned as described above are
evaluated at 12, 24 and 60 months.
Tertiary outcome: Sexual function: The sexual func-
tioning of the patients is measured by the validated,
gender-speciﬁc 14-item Changes in Sexual Functioning
Questionnaire (CSFQ).38 In addition, 14 explorative
questions concerning sexual well-being, body image
and sexological counselling will be asked. In order to
obtain representative control data, a portion of these
questions is duplicated from The National Health
Figure 5 Classification of hospitalisation for planned or acute reasons in the trial. MI, myocardial infarction.
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Interview Surveys (SUSY).39 Finally, to avoid confound-
ing, patients will be screened for symptoms of major
depression using the 10-item Major Depression Inventory
(MDI).40
Measurements: The patients will be seen at predeﬁned
intervals of 2, 4 and12 weeks and thereafter every third
month for 5 years. In addition, the participants will be
registered in the Danbio registry at every visit. Disease
activity will be measured by disease activity score calcu-
lated on 28 joints (DAS28-CRP).
Disability status will be self-reported according to the
Danish-validated version of the Stanford Health
Assessment Questionnaire (HAQ). Patient-estimated
global health, pain and fatigue will be assessed on a
visual analogue scale (VAS) 0–100 mm.41 Self-reported
health status will be measured by SF-12 health percep-
tion scales; scores range from 0 to 100, with higher
scores representing better health.42 43 Body weight and
height will be measured at baseline and BMI calculated
as BMI=weight/height squared (kg/m2). Smoking is
deﬁned as daily smoking, current or past smoking and
never smoking.44
A cumulated dose of intra-articular glucocorticosteroid
administered between baseline and after 1-year will be
registered. Blood samples will be taken to measure C
reactive protein (CRP), serological markers (IG-M
rheumatoid factor), anticyclic citrullinated peptide anti-
bodies (anti-CCP) and lipid status. Double reading of
the systolic and diastolic blood pressure will be obtained
on the right arm with the participant in a sitting pos-
ition after a 5 min rest with two measurements with
1–2 min between them.45 An overview of trial design,
visits and end points is shown in table 1.
Safety
It is the investigator’s responsibility to ensure that all
serious adverse reactions/adverse events (AE) are imme-
diately reported to the sponsor and the project leader,
who are responsible for notifying the regional biomed-
ical research ethics committee. Reports to the regional
Biomedical Research Ethics Committee must be accom-
panied by comments on the possible consequences for
the trial. The project leader is also responsible for
informing the participating departments of what a
Table 1 Trial design, visits and end points
Variable Baseline 12 months 24 months 60 months
Sex X
Age X
Height X
Current smoker X X1 X2 X3
Tender joints X X1 X2 X3
Swollen joints X X1 X2 X3
IgM-RF X
Anti-CCP X X4
C reactive protein X X1 X2 X3
Patient global X X1 X2 X3
Patient pain X X1 X2 X3
Patient fatigue X X1 X2 X3
LDL cholesterol X X1 X2 X3
HDL cholesterol X X1 X2 X3
Total cholesterol X X1 X2 X3
Triglycerides X X1 X2 X3
Body weight X X1 X2 X3
Blood pressure: systolic X X1 X2 X3
Blood pressure: diastolic X X1 X2 X3
Cardiovascular acute hospitalisation X X1 X2 X3
Cardiovascular disease X X1 X2 X3
CSFQ-14 X X1 X2 X3
MDI X X1 X2 X3
SF-12 X X1 X2 X3
LI-Sat X X1 X2 X3
Self-reported 15-item questionnaire on sexual activity X X1 X2 X3
Paper 1. Multifactorial intervention and cardiovascular disease in patients with early RA after a 1-year follow-up considering data marked with (1).
Paper 2. Multifactorial intervention and cardiovascular disease in patients with early RA after a 2-year follow-up considering data marked with (2).
Paper 3. Effect of a multifactorial intervention on mortality in patients with RA after 5 years of follow-up considering data marked with (3).
CCP, cyclic citrullinated peptide antibodies; CSFQ, Changes in Sexual Functioning Questionnaires; HDL, high-density lipoprotein; KRAMS,
nurse counselling regarding diet, smoking, alcohol use and exercise habits; LDL, low-density lipoprotein; Li-sat, Questions concerning sexual
well-being, body image and sexological counselling; MDI, Major Depression Inventory; NSJ, number of swollen joints; NTJ, number of tender
joints; RA, rheumatoid arthritis; RF, rheumatoid factor SF-12, short form 12-items health survey.
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serious adverse reaction/adverse event entails. It is also
the responsibility of the project leader to submit on an
annual basis, starting 1 year after approval of the study, a
list of serious unexpected adverse reactions that have
occurred in the period to the regional Biomedical
Research Ethics Committee. Standard AE and serious
adverse events will be systematically registered and
reported to the Danish Health and Medicines Authority.
The participants in the trial are treated in accordance
with national guidelines. Those patients who suffer
harm from trial participation will be referred to the
patient compensation association.
Randomisation
After the baseline assessment, the participants will be
randomly assigned to either the control group or the
intervention group. The randomisation sequence is
created using SAS (SAS V. 9.2) statistical software and is
stratiﬁed by centre with a 1:1 allocation using random
block sizes of 2, 4 and 6. The allocation sequence will be
concealed from the researcher enrolling and assessing
participants in sequentially numbered, opaque and
sealed envelopes. Aluminium foil inside the envelope
will be used to render the envelope impermeable to
intense light. After revealing the content of the enve-
lope, both patients and the treating rheumatologists are
aware of the allocation and the corresponding treat-
ment. Outcome assessors and data analysts will, however,
be kept blinded. Prior to the outcome assessments, the
patients will be asked by the research assistant not to
mention the treatment to which they have been
allocated.
Blinding
After assignment of the participants to the intervention,
the senior cardiologist (event committee) is blinded
when validating the cardiovascular end points after the
1-year, 2-year and 5-year follow-ups.
Data collection, management and confidentiality
All primary analyses will be performed on an
intention-to-treat basis; all patients randomised will be
included in the primary analyses. Study participation is
considered to be complete for any individual participant
at the time he or she had an occurrence of the primary
end point, had informed consent withdrawn, was unable
to be followed further because the study site closed, or
had been followed for at least September 2020. The
exposure time was calculated as the time between ran-
domisation and the ﬁrst major cardiovascular event, the
date of death, the date of the last study visit, the date of
withdrawal or loss to follow-up, or September 2020,
whichever came ﬁrst. Regarding conﬁdentiality, all data
will be electronically stored in electronic clinical data-
bases approved by the Danish health authorities, which
approved the procedure. The patient consent form and
the SUSY questionnaire is stored in paper form and kept
locked and at the investigator’s site.
Statistical methods
Sample size and power considerations
Assuming a constant rate of events of 10% per year,
among patients with RA allocated to the control group,
and a risk reduction with the ERACOR programme cor-
responding to 50%, it was decided to include a total of
300 patients with RA (150 patients in each group). For a
comparison of two independent binomial proportions
using Pearson’s χ2 statistic with a χ2 approximation with
a two-sided signiﬁcance level of 0.05 (p<0.05), a sample
size of 118 per group achieves a power of at least 90% of
patients having a composite of death from cardiovascu-
lar causes, non-fatal myocardioinfarction, non-fatal
stroke and cardiac revascularisation are 45% and 25%.
As illustrated in table 2, with 150 patients in each group
included in the intention-to–treat (ITT) population,
there is a reasonable statistical power (83%) even to
detect a difference between 25% and 12% of patients
having an event during the ﬁve years of observation.
Prespecification of the analysis
The primary cardiovascular disease end point is a com-
posite measure of death from cardiovascular causes,
non-fatal MI, non-fatal stroke and cardiac revascularisa-
tion after a 5-year follow-up. The primary end point is a
binary outcome, enabling interpretation from the rela-
tive beneﬁt and harm from the ‘ERACORI programme’
and, on the basis of the observed events in the control
group, we can communicate absolute beneﬁt and harm
as well.
The primary end point (60 months from baseline) will
be analysed with ‘survival analysis’ according to the ITT
principle, with event curves for the time to the ﬁrst
event based on the Kaplan-Meier analysis and treatments
being compared with the use of the log-rank test. A Cox
regression model is used to calculate the HR for the
primary end point. For the purpose of sensitivity, the
analyses will be adjusted for age, the duration of RA, sex,
clinical centre and cardiovascular status at baseline.
Binary outcomes: Logistic regression analysis and χ2
tests will be used to compare categorical variables.
Comparison between dichotomous outcome variables
will be presented as risk ratios (RRs) with 95% CIs, and
Table 2 Power calculation on different CVD prevalences
Scenario
Proportion
(Control)
Proportion
(ERACORI)
Statistical
power*
1 0.50 0.25 0.995
2 0.50 0.30 0.946
3 0.50 0.35 0.750
4 0.25 0.10 0.932
5 0.25 0.12 0.830
6 0.25 0.15 0.582
*χ2 approximation with a two-sided significance level of 0.05, with
a sample size of 150 patients with RA per group.
CVD, cardiovascular diseases; RA, rheumatoid arthritis.
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interpreted on the basis of the absolute beneﬁt or
harm via risk differences (RDs) with 95% CIs. The sen-
sitivity analyses will be modelled using logistic regression
analysis to investigate the relationship between these dis-
crete responses and a set of potentially confounding
variables. The logistic model is based on a General
Linear Model (GLM): a function of the mean of the
response variable is assumed to be linearly related to
the explanatory variables. The model will include treat-
ment and centre status as ﬁxed effects, with the base-
line value (if assessed) of the relevant variable as a
covariate.
Continuous outcomes: Measured variables are com-
pared by means of analysis of covariance, with baseline
values as covariates to adjust for differences between
the groups at randomisation. This analysis of covariance
will be modelled using the method of least squares to
ﬁt a GLM. The sensitivity analyses for the continuous
outcomes will be modelled using GLM. GLM handles
models relating one or several continuous dependent
variables to one or several independent variables. As
for the binary outcomes, the model will include treat-
ment and centre status as ﬁxed effects, with the base-
line value (if assessed) of the relevant variable as a
covariate.
Full analysis set
The primary analyses will be performed according to
the ITT principle. The ITT principle implies that the
primary analysis should include all randomised partici-
pants. Compliance with this principle would necessitate
a complete follow-up of all randomised participants for
study outcomes. In practice, this ideal may be difﬁcult to
achieve for different reasons that will not necessarily
introduce bias into the subsequent statistical analysis. In
this study, the term ‘full analysis set’ is used to describe
the analysis set, which is as complete as possible and as
close as possible to the ITT ideal of including all
randomised participants (ie, the ITT population).
Preservation of the initial randomisation in analysis is
important in preventing bias and in providing a secure
foundation for statistical tests. The full analysis set pro-
vides a conservative strategy. Under many circumstances,
it may also provide estimates of treatment effects which
are more likely to mirror those observed in subsequent
practice.
When data are incomplete at end point, we will
perform sensitivity analyses based on an imputation of
missing values using two different approaches: (1) mul-
tiple imputation with age, the duration of RA, sex, clin-
ical centre and cardiovascular status at baseline entered
as predictor variables and (2) imputation of ‘best’ and
‘worst’ case scenarios by replacing missing values with
‘good’ outcomes in one group and ‘bad’ outcomes in
the other group.46 Where complete cases and different
imputation techniques give different results, we will
attempt to understand why and report this in the
publications.
Per protocol set
The ‘per protocol’ set of participants is deﬁned as a
subset of the participants in the full analysis set who are
more compliant with the protocol, characterised by the
following criteria: Participants are deﬁned as per proto-
col if they have no more than one absence from a clin-
ical visit per year. One year in the analysis is deﬁned as
12 months (plus/minus 1 month).
Subgroups, interactions and covariates
Subgroup analysis will be performed regarding partici-
pants with diabetes type II, obese BMI≥30 kg/m2,
Smokers and seropositive patients, that is, positive
anti-CCP and/or positive IgM RF, and high disease activ-
ity (DAS28CRp >3.2 after 6 months of treatment).
Data monitoring
The ERACORI study is carried out in accordance with
the approved protocol and the applicable regulatory
requirements and legislations in this ﬁeld.
The role of the data monitoring committee (DMC) is
to register death from cardiovascular causes, non-fatal
MI, non-fatal stroke and cardiovascular revascularisation
and death by any cause after 1, 2, 5 and 10 years of
follow-up. Two authors (BBL and ALS) will go through
all patient records and register these data. In case of any
discrepancies identiﬁed, TE will make the ﬁnal decision.
DMC is independent from competing interests.
In case the DMC is registering a 50% higher mortality
rate from cardiovascular causes or a 50% higher preva-
lence of cardiovascular events after year one or year two
of follow-up in any of the study groups, the principal
investigator (TE) and the co-investigator (ALS) (The
trial management committee) are responsible for
informing the steering committee about the matter. The
trial management committee makes the ﬁnal decision to
terminate the trial.
ETHICS, DISSEMINATION, AUDITING AND DISCLOSURE
All patients must give their written informed consent.
The protocol is approved by the local ethics committee
(DK S-2014007) and the Danish Health and Medicines
Authority and performed in accordance with the
Declaration of Helsinki47 and Oviedo. A report will be
submitted to the ethics committee yearly; in case of
changes in the Danish national guidelines for the
comorbidity strategy, the ethics committee will be con-
tacted. The trial is registered at Clinical Trials.Gov (NCT
02246257).
Auditing: The Danish national health authorities as
well as the scientiﬁc committee do not require auditing
for this speciﬁc study.
The scientiﬁc integrity of the project requires that the
data from the ERACORI trial sites will be analysed in its
entity. Thus, an individual centre is not supposed to
report data collected from this centre alone. All abstracts
and publications are expected to protect the integrity of
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the major objective of the study. The recommendations
considering the timing and presentation of end point
data and the meetings at which they might be pre-
sented will be given by the steering committee. The
review process in each paper or abstract will be distribu-
ted and reviewed by all principal investigators in the
study prior to submission to a peer-reviewed journal or
national or international conference. The study results
will be released to the participating physicians, patients
and the general medical community.
Two internal monitors will ensure that all data have
been entered correctly and in accordance with the
protocol. If data are missing, queries will be sent out
electronically to the study sites. Disclosures for all the
authors are accessible at the Danish Health and
Medicines Authority in the updated version.
DISCUSSION
The ERACORI study is expected to contribute signiﬁ-
cant new knowledge about CVD prevention strategies in
early patients with RA, thereby ensuring optimal treat-
ment for CVD risk factors in this high-risk population.
The ERACORI intervention is a multidimensional
intervention. We know that it is not possible to clear out
which part is most efﬁcient. Multidimensional interven-
tions are in general considered more efﬁcient, espe-
cially in CVD protection. Multifactorial risk reduction
requires multifactorial intervention. Our study is
inspired by the Steno 2 study in T2DM, which has
shown remarkable CVD risk reduction by applying
multifactorial intervention in a Danish high-risk popula-
tion of patients with T2DM. Post-study evaluation of the
results has indicated that most of the CVD beneﬁt came
from statin therapy, but it is clearly the combined inter-
vention that is beneﬁcial.20 In RA, it has further been
evaluated in a meta-analysis this year that the anti-
inﬂammatory effect of statins in RA is signiﬁcant and
beneﬁcial, resulting in lower disease activity in the 15
RA cohorts studied;48 that is why the secondary
outcome evaluating disease activity was chosen. In the
CARRE study on RA, both elevated systolic blood pres-
sure and impaired renal function (measured as glom-
erular ﬁltration rate (GFR)) were associated with
increased risk of MI.49
Microalbuminuria is a somewhat overlooked CVD risk
factor in a general population, despite being present in
up to 7%. In hypertensive patients, treatment and reduc-
tion in microalbuminuria is associated with improved
CVD outcome, not to mention cases of patients with
T2DM. Microalbuminuria is thought to reﬂect general
vascular endothelial dysfunction, and as such a predictor
of CVD. Since we think the RA population in this study
is paralleled to a T2DM population in terms of CVD
risk, we have included microalbuminuria as a risk factor.
As mentioned above, even small declines in the GFR are
predictive of MI in RA.49
We have chosen a design evaluating the effect of multi-
factorial intervention. As such, our study is designed to
yield optimal clinical beneﬁt, not to investigate and
measure the effect of single risk factor intervention.
However, some may worry that the patients with RA in
the control group might receive insufﬁcient counselling
compared to patients without RA and other high CVD
risk groups. The GP receives an electronic patient-ﬁle
notiﬁcation that the patient is participating in the
ERACORI protocol. Regarding patients in the control
group, the GP will receive an electronic notiﬁcation to
treat diabetes, hypertension or CVD if present according
to the guidelines. The patient has to arrange the
appointment with the GP. The GP does not receive
information about the ERACORI study protocol or the
study hypothesis, but is of course free to search for the
study in http://www.clinicaltrials.gov.
We are aware of the risk that patients might receive
insufﬁcient CVD counselling compared to patients
without RA and other CVD high-risk groups. However,
the aforementioned procedure is the standard care for
CVD prevention and treatment in patients with RA in
Denmark. At present, there is no tradition in the
Danish rheumatology association to provide CVD pre-
vention counselling as a standard along with the RA
treatment. It is our hope that the results of the
ERACORI study can contribute by showing how to make
the most efﬁcient strategy for CVD prevention in
patients with early RA.
When we designed the intervention part of the
ERACORI study we were inspired by the Steno II studies
on patients with T2DM20 21 50 since the diabetes II
population’s CVD risk is similar to that of patients with
RA. The choice of recommending simvastatin 40 mg
when LDL>2, 5 mmol/L is in line with the Danish
guideline for cholesterol treatment of patients with
T2DM.25 This is the reason why we have chosen not to
follow the ESC guideline on this aspect.
Furthermore, it has been shown that ECS SCORE
underestimates the CVD risk among patients with RA.51
In addition to a cholesterol lowering effect, simvastatin
also has an anti-inﬂammatory effect which might be
beneﬁcial regarding prevention of CVD in patients with
RA.52 The chronic inﬂammation and the endothelial
dysfunction in patients with RA are not taken into
account in the ERC guidelines SCORE risk estimation
algorithm. We have used the ERC guidelines in design-
ing the counselling regarding behavioural change and
behavioural risk factors for CVD.
Since the CVD risk of the T2DM population is similar
to that of patients with RA, we consider it relevant to
include 300 patients with RA in the ERACORI study.20 21
In the steno II studies, it was possible with 166 patients
with T2DM included to detect a signiﬁcant difference in
the CVD outcome between the two groups. The TRACE
study was a single factor intervention study with 40 mg
atorvastatin versus placebo on patients with RA with
10 years’ disease duration, which was prematurely
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terminated due to the CVD event rate in the 40 mg ator-
vastatin group as well as in the placebo group. However,
a higher number of patients are usually required when
investigating single factor interventions compared to
multidimensional interventions.53
If the ERACORI intervention programme is shown to
be beneﬁcial, implementation in daily clinical practice
will be feasible.
A weakness is the non-blinded design. The rheuma-
tologist and the patient were not blinded to the allo-
cated intervention, which potentially could lead to bias.
However, the outcome assessors of the cardiovascular
end point were blinded to the patient intervention
status, which has previously been shown to be a valid
method.20 21 50 To the best of our knowledge, this is the
ﬁrst RCT study to investigate the effect of an intensive
multidimensional intervention aiming at preventing
CVD among patients with early RA. The results of the
study will be of importance for rheumatologists who
treat patients with RA and can potentially change the
way we monitor patients with RA and target treatment
against CVD risk factors as well as RA in order to obtain
better disease control and decrease the overall disease
burden of our patients with RA with the possibility of
improving survival.
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